Biochemical and Biophysical Research Communications . 2007 Nov 29 [Epub ahead of print] [Link]
Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B.
CHU Montpellier, Hopital St Eloi, Institut de Recherches en BiothÃ©rapie, Av Augustin Fliche, 34285 MONTPELLIER Cedex 5, France; INSERM, U847, Montpellier F-34197, France.
CD200 was recently described as a new prognosis factor in multiple myeloma and acute myeloid leukemia. CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. We investigated the expression of CD200 in cancer using publicly available gene expression data. CD200 gene expression in normal or malignant human tissues or cell lines was obtained from the Oncomine Cancer Microarray database, Amazonia database and the ITTACA database. We found significant overexpression of CD200 in renal carcinoma, head and neck carcinoma, testicular cancer, malignant mesothelioma, colon carcinoma, MGUS/smoldering myeloma, and in chronic lymphocytic leukemia compared to their normal cells or their tissue counterparts. Moreover, we show that CD200 expression is associated with tumor progression in various cancers. Taken together, these data suggest that CD200 is a potential therapeutic target and prognostic factor for a large array of malignancies.
Keywords: Tumor immunity; Cell surface molecules; Tolerance; CD200; Therapeutic target